406 related articles for article (PubMed ID: 27438595)
1. Drug search for leishmaniasis: a virtual screening approach by grid computing.
Ochoa R; Watowich SJ; Flórez A; Mesa CV; Robledo SM; Muskus C
J Comput Aided Mol Des; 2016 Jul; 30(7):541-52. PubMed ID: 27438595
[TBL] [Abstract][Full Text] [Related]
2. Auranofin is an apoptosis-simulating agent with in vitro and in vivo anti-leishmanial activity.
Sharlow ER; Leimgruber S; Murray S; Lira A; Sciotti RJ; Hickman M; Hudson T; Leed S; Caridha D; Barrios AM; Close D; Grögl M; Lazo JS
ACS Chem Biol; 2014 Mar; 9(3):663-72. PubMed ID: 24328400
[TBL] [Abstract][Full Text] [Related]
3. Computational and Investigative Study of Flavonoids Active Against Typanosoma cruzi and Leishmania spp.
Ribeiro FF; Junior FJ; da Silva MS; Scotti MT; Scotti L
Nat Prod Commun; 2015 Jun; 10(6):917-20. PubMed ID: 26197515
[TBL] [Abstract][Full Text] [Related]
4. Repurposing of known drugs for leishmaniasis treatment using bioinformatic predictions, in vitro validations and pharmacokinetic simulations.
Bustamante C; Ochoa R; Asela C; Muskus C
J Comput Aided Mol Des; 2019 Sep; 33(9):845-854. PubMed ID: 31612362
[TBL] [Abstract][Full Text] [Related]
5. Leishmaniasis drug discovery: recent progress and challenges in assay development.
Zulfiqar B; Shelper TB; Avery VM
Drug Discov Today; 2017 Oct; 22(10):1516-1531. PubMed ID: 28647378
[TBL] [Abstract][Full Text] [Related]
6. Developing imidazole analogues as potential inhibitor for Leishmania donovani trypanothione reductase: virtual screening, molecular docking, dynamics and ADMET approach.
Pandey RK; Sharma D; Bhatt TK; Sundar S; Prajapati VK
J Biomol Struct Dyn; 2015; 33(12):2541-53. PubMed ID: 26305585
[TBL] [Abstract][Full Text] [Related]
7. In silico search of energy metabolism inhibitors for alternative leishmaniasis treatments.
Silva LA; Vinaud MC; Castro AM; Cravo PV; Bezerra JC
Biomed Res Int; 2015; 2015():965725. PubMed ID: 25918726
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase 1B as a target against leishmaniasis.
D'Annessa I; Castelli S; Desideri A
Mini Rev Med Chem; 2015; 15(3):203-10. PubMed ID: 25769969
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic insights into the dual inhibition strategy for checking Leishmaniasis.
Grover A; Katiyar SP; Jeyakanthan J; Dubey VK; Sundar D
J Biomol Struct Dyn; 2012; 30(4):474-87. PubMed ID: 22694167
[TBL] [Abstract][Full Text] [Related]
10. Exploration of New and Potent Lead Molecules Against CAAX Prenyl Protease I of Leishmania donovani Through Pharmacophore Based Virtual Screening Approach.
Prabhu SV; Tiwari K; Suryanarayanan V; Dubey VK; Singh SK
Comb Chem High Throughput Screen; 2017; 20(3):255-271. PubMed ID: 28116998
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and characterization of a pyridine-2-thiol N-oxide gold(I) complex with potent antiproliferative effect against Trypanosoma cruzi and Leishmania sp. insight into its mechanism of action.
Vieites M; Smircich P; Guggeri L; Marchán E; Gómez-Barrio A; Navarro M; Garat B; Gambino D
J Inorg Biochem; 2009 Oct; 103(10):1300-6. PubMed ID: 19361864
[TBL] [Abstract][Full Text] [Related]
12. Repurposing Glyburide as Antileishmanial Agent to Fight Against Leishmaniasis.
Rub A; Shaker K; Kashif M; Arish M; Dukhyil AAB; Alshehri BM; Alaidarous MA; Banawas S; Amir K
Protein Pept Lett; 2019; 26(5):371-376. PubMed ID: 30827222
[TBL] [Abstract][Full Text] [Related]
13. Targeting pteridine reductase 1 and dihydrofolate reductase: the old is a new trend for leishmaniasis drug discovery.
das Neves GM; Kagami LP; Gonçalves IL; Eifler-Lima VL
Future Med Chem; 2019 Aug; 11(16):2107-2130. PubMed ID: 31370699
[TBL] [Abstract][Full Text] [Related]
14. The role of heparan sulfate in host macrophage infection by
Maciej-Hulme ML; Skidmore MA; Price HP
Biochem Soc Trans; 2018 Aug; 46(4):789-796. PubMed ID: 29934302
[TBL] [Abstract][Full Text] [Related]
15. In silico work flow for scaffold hopping in Leishmania.
Waugh B; Ghosh A; Bhattacharyya D; Ghoshal N; Banerjee R
BMC Res Notes; 2014 Nov; 7():802. PubMed ID: 25399834
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of dihydroorotate dehydrogenase from Leishmania major.
Cordeiro AT; Feliciano PR; Pinheiro MP; Nonato MC
Biochimie; 2012 Aug; 94(8):1739-48. PubMed ID: 22542640
[TBL] [Abstract][Full Text] [Related]
17. Protease inhibitors in potential drug development for Leishmaniasis.
Das P; Alam MN; Paik D; Karmakar K; De T; Chakraborti T
Indian J Biochem Biophys; 2013 Oct; 50(5):363-76. PubMed ID: 24772958
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic insights into mode of actions of novel oligopeptidase B inhibitors for combating leishmaniasis.
Goyal S; Grover S; Dhanjal JK; Goyal M; Tyagi C; Chacko S; Grover A
J Mol Model; 2014 Mar; 20(3):2099. PubMed ID: 24567150
[TBL] [Abstract][Full Text] [Related]
19. Screening natural products database for identification of potential antileishmanial chemotherapeutic agents.
Venkatesan SK; Saudagar P; Shukla AK; Dubey VK
Interdiscip Sci; 2011 Sep; 3(3):217-31. PubMed ID: 21956744
[TBL] [Abstract][Full Text] [Related]
20. Virtual screening to identify Leishmania braziliensis N-myristoyltransferase inhibitors: pharmacophore models, docking, and molecular dynamics.
de Carvalho Gallo JC; de Mattos Oliveira L; Araújo JSC; Santana IB; Dos Santos Junior MC
J Mol Model; 2018 Aug; 24(9):260. PubMed ID: 30159742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
